Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
(|) |
No edit summary |
||
(13 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
*symptomatic epilepsy | *symptomatic epilepsy | ||
*provoked epilepsy | *provoked epilepsy | ||
*cryptogenic epilepsy | *[[cryptogenic epilepsy]] | ||
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03041.x/epdf The etiologic classification of epilepsy]</ref> | <ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03041.x/epdf The etiologic classification of epilepsy]</ref> | ||
It is difficult to distinguish between genetic and cryptogenic syndromes. | It is difficult to distinguish between genetic and cryptogenic syndromes. | ||
Line 34: | Line 34: | ||
|[[Levetiracetam XR|xr]] | |[[Levetiracetam XR|xr]] | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''oxcarbazepine''' ||[[ | |align="left" style="background:#99ff99"|'''oxcarbazepine''' ||[[oxcarbazepine]] | ||
|xr | |xr | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|''' | |align="left" style="background:#99ff99"|'''[[phenytoin]]''' ||[[...]] | ||
|xr | |xr | ||
|-style="vertical-align:top; background:#ffffff;" | |-style="vertical-align:top; background:#ffffff;" | ||
Line 52: | Line 52: | ||
|} | |} | ||
[[File:Riluzole.svg.png|thumb|[[riluzole]]]] | |||
[[File:2000px-Sultiame.svg.png|thumb|sulthiame]] | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures] | ||
Line 83: | Line 85: | ||
[http://www.scholarpedia.org/w/index.php?title=Models_of_epilepsy&oldid=140675 Models of epilepsy] | [http://www.scholarpedia.org/w/index.php?title=Models_of_epilepsy&oldid=140675 Models of epilepsy] | ||
[https://www.frontiersin.org/articles/10.3389/fphar.2017.00661/full purinergic signalling:therapeutic developments] | |||
[https://www.ncbi.nlm.nih.gov/pubmed/28993753 Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes] | |||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613169/ Ranking the Leading Risk Factors for Sudden Unexpected Death in Epilepsy] | |||
[[Lennox–Gastaut_syndrome|Lennox-Gastaut Syndrome]] | [[Lennox–Gastaut_syndrome|Lennox-Gastaut Syndrome]] | ||
[[BECTS]] | |||
[[Dravet's syndrome]] | [[Dravet's syndrome]] | ||
[[Status epilepticus]] | [[Status epilepticus]] | ||
:[[Panayiotopoulos syndrome]] | :[[Panayiotopoulos syndrome]] | ||
:[[epilepsia partialis continua]] | |||
[[West's syndrome]] | [[West's syndrome]] | ||
[[Ohtahara syndrome]] | |||
[[Pretzel syndrome]] | |||
[[Doose syndrome]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Neurological disorder]] | [[Category:Neurological disorder]] | ||
Latest revision as of 23:16, 29 January 2023
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance with AED[5]
Medicines | ||||
type | ,,, | ,,,, | ||
INN | Generic | slow release | ||
carbamazepine | normal | xr | ||
lamotrigine | normal | Lamictal XR[6] | ||
levetiracetam | normal | xr | ||
oxcarbazepine | oxcarbazepine | xr | ||
phenytoin | ... | xr | ||
valproate | xr | |||
topiramate | xr | |||
AED |
Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline
ILAE Classification
[7] [8] [9] [10] ILAE Overview
See also
A new perspective for Epileptic Disorders
Links
Epilepsies: diagnosis and management clinical guide
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
purinergic signalling:therapeutic developments
Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes
Ranking the Leading Risk Factors for Sudden Unexpected Death in Epilepsy
References: |
|